{
  "schemaVersion": 1,
  "organisationId": "O-8af6eaaac21c44ce9d6718aa65619db4",
  "slug": "edgewise-therapeutics-inc",
  "name": "Edgewise Therapeutics, Inc.",
  "updatedAt": "2026-10-02T13:31:39.895888Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious cardiovascular diseases. Its mission is to change the lives of patients and families affected by these conditions. [P147647090]\n\nIts lead candidate, oral cardiac sarcomere modulator EDG-7500, is being studied for obstructive and nonobstructive hypertrophic cardiomyopathy. The company is also developing EDG-15400 and conducting preclinical cardiometabolic research. [P147647090] In July 2026, Edgewise completed the sale of its sevasemten and muscular-dystrophy program to Servier, sharpening its focus on cardiovascular disease. [P147647206]\n\nEdgewise is headquartered in Boulder, Colorado, and was incorporated in Delaware in 2017. [P14314086] It remains a development-stage company: its 2025 annual filing reported no approved products and no revenue, while its 2026 second-quarter statements report no product-revenue line. [P96594164][T16897249]\n[P147647090][P147647206][P14314086][P96594164][T16897249]",
      "updatedAt": "2026-10-02T13:31:39.895888Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Edgewise’s pipeline includes EDG-7500, an oral, selective cardiac sarcomere modulator being developed for obstructive and nonobstructive hypertrophic cardiomyopathy. The company describes its intended action as slowing early cardiac contraction to improve relaxation. After reporting positive topline results from the Phase 2 CIRRUS-HCM trial, it targeted Phase 3 initiation for the fourth quarter of 2026. [P147646995][P147647090][https://edgewisetx.com/science/edg-7500/]\n\nEDG-15400 is an oral, next-generation cardiac sarcomere modulator being developed for heart failure with preserved ejection fraction. Phase 1 dosing in healthy adults was completed, and the company reported plans for Phase 2 in the second half of 2026. EDG-003 is a cardiometabolic-focused discovery program; it had not entered clinical trials. [P147646995][P147647090][P147647311][https://edgewisetx.com/science/edg-15400/][https://edgewisetx.com/science/pipeline/]\n\nSevasemten and related muscular-dystrophy program assets were sold to Servier in a transaction that closed July 10, 2026, so they are no longer Edgewise-developed products. Edgewise reported no approved products for commercial sale and no product revenue; the available information does not identify a separate services offering or product-sales percentage. [P147646996][P147648004][P147647311]\n[P147646995][P147647090][P147647311][P147646996][P147648004][https://edgewisetx.com/science/edg-7500/][https://edgewisetx.com/science/edg-15400/][https://edgewisetx.com/science/pipeline/]",
      "updatedAt": "2026-10-02T13:31:39.895888Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Edgewise Therapeutics is headquartered in Boulder, Colorado, where it leases office and laboratory space and has many of its personnel. Its reported Boulder facilities comprise approximately 18,614 square feet of office/lab space and 9,624 square feet of additional office space. [P147647764][P147647246] The company’s listed headquarters address is 1715 38th St, Boulder, CO 80301. [https://edgewisetx.com/company/contact-us/]\n\nThe company has described clinical-trial activity in the United States and exposure to trials in Israel and certain countries in Europe and Australasia; it has not provided a country-by-country site count. [P147647482][P147647627] These disclosures concern clinical trials and do not establish offices or other facilities in those regions.\n\nAs of its 2026 second-quarter filing, Edgewise reported no products approved for commercial sale and no revenue, so there was no geographic sales or revenue breakdown to report. [P147647311] The filing does not quantify employee distribution or foreign-vendor exposure; it notes that some vendors outside the United States invoice in foreign currencies. [P147647764][P147647258]\n[P147647764][P147647246][https://edgewisetx.com/company/contact-us/][P147647482][P147647627][P147647311][P147647258][https://edgewisetx.com/company/contact-us/]",
      "updatedAt": "2026-10-02T13:31:39.895888Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Edgewise Therapeutics reports one operating and reportable segment: the discovery, development, and manufacture of drug products for muscular disorders. It reviews performance and allocates resources on a consolidated basis, rather than reporting separate business or product segments. [P114730373]\n\nThis single segment represents 100% of the company’s reported business activity; however, no revenue-based contribution percentage can be calculated because the company reported that it had not generated revenue to date. Its disclosed development programs are not reported as separate segments. [P147647318]\n[P114730373][P147647318]",
      "updatedAt": "2026-10-02T13:31:39.895888Z"
    },
    {
      "type": "HISTORY",
      "text": "Founded in 2017 by Alan Russell, Peter Thompson and Badreddin Edris, Edgewise Therapeutics began clinical testing of its muscle-disorder drug candidate EDG-5506 in 2020. The company went public on Nasdaq in March 2021. [P46191670][P76829689][P92302638]\n\nFrom 2022 to 2024, Edgewise advanced EDG-5506—later named sevasemten—through Phase 2 studies in Becker muscular dystrophy, including a potentially registrational cohort announced in 2023. It also began clinical development of the cardiac candidate EDG-7500 in 2023 and reported clinical data from both programs in 2024. [P90997952][P93715536][P5362215][P73670566]\n\nIn 2025, the company reported Phase 2 data for sevasemten in Duchenne muscular dystrophy. In July 2026, Servier completed its acquisition of sevasemten and Edgewise’s muscular-dystrophy business; Edgewise characterized the transaction as a transition to a cardiovascular focus centered on EDG-7500. [P81053023][P39770428][P147646649][P147646651]\n[P46191670][P76829689][P92302638][P90997952][P93715536][P5362215][P73670566][P81053023][P39770428][P147646649][P147646651]",
      "updatedAt": "2026-10-02T13:31:39.895888Z"
    }
  ],
  "sources": [
    {
      "id": "P147647090",
      "href": "https://app.finbar.com/go?id=P147647090",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147647206",
      "href": "https://app.finbar.com/go?id=P147647206",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P14314086",
      "href": "https://app.finbar.com/go?id=P14314086",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7420629755534138ac04453c4a365e34"
    },
    {
      "id": "P96594164",
      "href": "https://app.finbar.com/go?id=P96594164",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7420629755534138ac04453c4a365e34"
    },
    {
      "id": "T16897249",
      "href": "https://app.finbar.com/go?id=T16897249",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147646995",
      "href": "https://app.finbar.com/go?id=P147646995",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "https://edgewisetx.com/science/edg-7500/",
      "href": "https://edgewisetx.com/science/edg-7500/",
      "label": "edgewisetx.com"
    },
    {
      "id": "P147647311",
      "href": "https://app.finbar.com/go?id=P147647311",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "https://edgewisetx.com/science/edg-15400/",
      "href": "https://edgewisetx.com/science/edg-15400/",
      "label": "edgewisetx.com"
    },
    {
      "id": "https://edgewisetx.com/science/pipeline/",
      "href": "https://edgewisetx.com/science/pipeline/",
      "label": "edgewisetx.com"
    },
    {
      "id": "P147646996",
      "href": "https://app.finbar.com/go?id=P147646996",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147648004",
      "href": "https://app.finbar.com/go?id=P147648004",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147647764",
      "href": "https://app.finbar.com/go?id=P147647764",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147647246",
      "href": "https://app.finbar.com/go?id=P147647246",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "https://edgewisetx.com/company/contact-us/",
      "href": "https://edgewisetx.com/company/contact-us/",
      "label": "edgewisetx.com"
    },
    {
      "id": "P147647482",
      "href": "https://app.finbar.com/go?id=P147647482",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147647627",
      "href": "https://app.finbar.com/go?id=P147647627",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P147647258",
      "href": "https://app.finbar.com/go?id=P147647258",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P114730373",
      "href": "https://app.finbar.com/go?id=P114730373",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7420629755534138ac04453c4a365e34"
    },
    {
      "id": "P147647318",
      "href": "https://app.finbar.com/go?id=P147647318",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-2096bff23aea4711816b655c4f8d39a1"
    },
    {
      "id": "P46191670",
      "href": "https://app.finbar.com/go?id=P46191670",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2021 Y)",
      "documentId": "D-214e4a2686774534944f4fbcd0f63d04"
    },
    {
      "id": "P76829689",
      "href": "https://app.finbar.com/go?id=P76829689",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2021 Y)",
      "documentId": "D-214e4a2686774534944f4fbcd0f63d04"
    },
    {
      "id": "P92302638",
      "href": "https://app.finbar.com/go?id=P92302638",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2022 Y)",
      "documentId": "D-8a871799333846ef9de9e5770a70122a"
    },
    {
      "id": "P90997952",
      "href": "https://app.finbar.com/go?id=P90997952",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2022 Q 2)",
      "documentId": "D-756e096687f14caeb5206e1e938a8d54"
    },
    {
      "id": "P93715536",
      "href": "https://app.finbar.com/go?id=P93715536",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2023 Y)",
      "documentId": "D-855737661ffc43ec8d08b3b4153e7a0b"
    },
    {
      "id": "P5362215",
      "href": "https://app.finbar.com/go?id=P5362215",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2023 Y)",
      "documentId": "D-855737661ffc43ec8d08b3b4153e7a0b"
    },
    {
      "id": "P73670566",
      "href": "https://app.finbar.com/go?id=P73670566",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2024 Y)",
      "documentId": "D-6e9c9b55d9bf4f409c7d84765632158c"
    },
    {
      "id": "P81053023",
      "href": "https://app.finbar.com/go?id=P81053023",
      "label": "Edgewise Therapeutics, Inc. — Full financial report (2026 Q 1)",
      "documentId": "D-1faefb25eeca4292b3c7fdbf3f3fb1c7"
    },
    {
      "id": "P39770428",
      "href": "https://app.finbar.com/go?id=P39770428",
      "label": "Edgewise Therapeutics, Inc. — Press release (2025 Q 3)",
      "documentId": "D-5a19fdf6e22b45028e2120ce0a7efcaf"
    },
    {
      "id": "P147646649",
      "href": "https://app.finbar.com/go?id=P147646649",
      "label": "Edgewise Therapeutics, Inc. — Press release (2026 Q 2)",
      "documentId": "D-4c74a66794d94cf98db86b36abb995d6"
    },
    {
      "id": "P147646651",
      "href": "https://app.finbar.com/go?id=P147646651",
      "label": "Edgewise Therapeutics, Inc. — Press release (2026 Q 2)",
      "documentId": "D-4c74a66794d94cf98db86b36abb995d6"
    }
  ]
}